About Propagenix
Founded in 2014, Propagenix developed and commercialized innovative cellular technologies that enabled the production and delivery of the next generation of tissue therapeutics. Fueled by the needs of patients who suffer from diseases involving epithelial barrier tissue dysfunction and injury, Propagenix provided best-in-class cell bioproduction platforms for regenerative therapies through internal development and collaborative partnerships with biopharma companies.
In January 2024, STEMCELL Technologies, Canada’s largest biotech company, announced the acquisition of Propagenix Inc. This ensures that Propagenix’s assets will continue to serve the life science research community. To learn more about the acquisition and the status of the product portfolio, read the news article and explore the resources below:
STEMCELL Technologies Announces Acquisition of Propagenix Inc.
Canadian acquisition of a U.S.-based biotechnology company is the first in STEMCELL’s history.
| Conditional Reprogramming Medium | 3T3-J2 Irradiated Feeder Cells | Conditioned Medium | EpiX Medium |
 |
 |
 |
 |
|
STEMCELL Catalog #100-0352 Recommended Applications: Epithelial cell expansion.
|
STEMCELL Catalog #100-0353 Recommended Applications: Optimized to support epithelial cell expansion in Conditional Reprogramming Medium.
|
DISCONTINUED Recommended Actions: Culture 3T3-J2 Irradiated Cells in Conditional Reprogramming Medium to produce Conditioned Medium using STEMCELL-validated products. Contact STEMCELL Technologies’ Product and Scientific Support team or your STEMCELL sales representative for any questions you may have. |
DISCONTINUED Recommended Actions: Transition to STEMCELL alternative products derived from EpiX technology. Recommended Products:
|